-York Tomita Researcher Activity Profile

Research Author Detailed Information 

York Tomita Publication Rate By Year

York Tomita has published 1 paper(s) in 2004, 2 paper(s) in 2005, 1 paper(s) in 2006, 9 paper(s) in 2007, for a total of 13 research publications in total.

York Y Tomita Author Information

LAST NAME: tomita

FIRST NAME: york

INITIALS: Y

AFFILIATION:

Papers

York Tomita's Publication Record

1. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. Year Published: 2006
Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
2. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Year Published: 2007
Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, USA.
3. Exploration of backbone space in foldamers containing alpha- and beta-amino acid residues: developing protease-resistant oligomers that bind tightly to the BH3-recognition cleft of Bcl-xL. Year Published: 2007
Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA.
4. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Year Published: 2007
Interdisciplinary Program in Neuroscience & Department of Pharmacology, Georgetown University, Washington, DC, USA.
5. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Year Published: 2007
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
6. Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. Year Published: 2007
Department of Biochemistry, Molecular and Cell Biology, and Georgetown University, Washington, DC 20007, USA.
7. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Year Published: 2007
Interdisciplinary Program in Neuroscience & Department of Pharmacology, Georgetown University, Washington, DC, USA.
8. Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. Year Published: 2007
Department of Biochemistry, Molecular and Cell Biology, and Georgetown University, Washington, DC 20007, USA.
9. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Year Published: 2007
Interdisciplinary Program in Neuroscience & Department of Pharmacology, Georgetown University, Washington, DC, USA.
10. Structure-based design of potent, conformationally constrained Smac mimetics. Year Published: 2004
Departments of Internal Medicine and Medicinal Chemistry and Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
11. Structure-based design of potent non-peptide MDM2 inhibitors. Year Published: 2005
Departments of Internal Medicine and Medicinal Chemistry and Comprehensive Cancer Center, and Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
12. Chimeric (alpha/beta + alpha)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition. Year Published: 2005
Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, USA.
13. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Year Published: 2007
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.